Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:42:21.752Z.
Calculation as of: 2026-10-06T14:42:21.752Z.
Quote observation: 2026-10-06T14:37:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2239cca652f31aeacf416f33e6d20b1e6c1b9088f917a2c9fa2f7c7bfc29848
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2014-06-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$7.37M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $7.33M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.37M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.35M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.33M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.09M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | N/A | 1.99x | 10.75x | 10.75x |
| Aclarion, Inc. (ACON)vs › | $6.83M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2014-06-30 | 57089.23x |
| 2014-06-27 | 57190.53x |
| 2014-06-26 | 59909.79x |
| 2014-06-25 | 56385.00x |
| 2014-06-24 | 54269.89x |
| 2014-06-23 | 64138.80x |
| 2014-06-20 | 64238.88x |
| 2014-06-19 | 50343.56x |
| 2014-06-18 | 54169.81x |
| 2014-06-17 | 51551.85x |
| 2014-06-16 | 51551.85x |
| 2014-06-13 | 51551.85x |
| 2014-06-12 | 51551.85x |
| 2014-06-11 | 51551.85x |
| 2014-06-10 | 51350.47x |
| 2014-06-09 | 50343.56x |
| 2014-06-06 | 61419.54x |
| 2014-06-05 | 42892.44x |
| 2014-06-04 | 42892.44x |
| 2014-06-03 | 34031.66x |
| 2014-06-02 | 34031.66x |
| 2014-05-30 | 34031.66x |
| 2014-05-29 | 34031.66x |
| 2014-05-28 | 30608.17x |
| 2014-05-27 | 31313.62x |
| 2014-05-23 | 36951.08x |
| 2014-05-22 | 27888.91x |
| 2014-05-21 | 27888.91x |
| 2014-05-20 | 27888.91x |
| 2014-05-19 | 27888.91x |
| 2014-05-16 | 27888.91x |
| 2014-05-15 | 26781.93x |
| 2014-05-14 | 26882.01x |
| 2014-05-13 | 26882.01x |
| 2014-05-12 | 26882.01x |
| 2014-05-09 | 26580.54x |
| 2014-05-08 | 26580.54x |
| 2014-05-07 | 27990.21x |
| 2014-05-06 | 25976.40x |
| 2014-05-05 | 26781.93x |
